8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
REGENERON PHARMACEUTICALS, INC. (REGN)

Regeneron ($REGN) issued a press release on Jan 30, 2026 announcing financial & operating results for the…

Filed with the SEC on · Summarized by InvestorsBot

Regeneron ($REGN) issued a press release on Jan 30, 2026 announcing financial & operating results for the quarter and year ended Dec 31, 2025. Press release furnished to the SEC as Exhibit 99.1. 📢🧾 #earnings #8K #biotech

The 8‑K notes the information (Exhibit 99.1) is furnished—not "filed"—under Section 18 of the Exchange Act and is not incorporated by reference into Securities Act filings unless expressly stated. ⚖️ $REGN #SEC #investing

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from REGENERON PHARMACEUTICALS, INC.

Regeneron filed an 8‑K (Item 9.01) on Jan 30, 2026: Exhibit 99.1 = press release reporting Q4 & full‑year…

8-K · January 30, 2026

Regeneron filed an 8‑K (1/12/26) attaching Exhibit 99.1 — a Jan 12, 2026 presentation by CEO Leonard S.

8-K · January 12, 2026

Regeneron ($REGN) on 2026-01-12 furnished a Regulation FD presentation (Exhibit 99.1) referenced in Item…

8-K · January 12, 2026

Regeneron says Q4 2025 will include an acquired IPR&D charge of ~ $19M pre-tax, reducing GAAP and non‑GAAP…

8-K · January 12, 2026